GPCM
VNDA icon

Granite Point Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Granite Point Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-20,000
Closed -$208K – 88
2014
Q3 		$208K Sell
20,000
-30,000
-60% -$393K 0.1% 77
2014
Q2 		$809K Sell
50,000
-7,600
-13% -$101K 0.56% 44
2014
Q1 		$936K Buy
+57,600
New +$819K 0.67% 48

Other funds holding VNDA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Granite Point Capital Management's VNDA Position: Q4 2014 in Review

Granite Point Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2014, closing a stake of 20,000 shares — an estimated $208K sold.

Granite Point Capital Management first reported a position in VNDA in Q1 2014 and held it in 3 quarters. The position peaked at $936K in Q1 2014. 109 funds tracked by Wall St. Rank hold VNDA as of Q4 2014.

  • Granite Point Capital Management reported no remaining Vanda Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Granite Point Capital Management sold 20,000 Vanda Pharmaceuticals shares in Q4 2014, an estimated $208K.
  • Granite Point Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • Granite Point Capital Management's Vanda Pharmaceuticals position peaked at $936K in Q1 2014.
  • 109 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2014.

Based on Granite Point Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.